Iclusig (ponatinib), a tyrosine
kinase inhibitor recently approved
for PBS funding is the subject of
this week’s Repatriation General
Hospital Pharmacy E-Bulletin.
The indications for the use of
the product are detailed along
with some elements of the
phase II trial which tipped the
approval, dosing, drug interactions
of which to be aware and the
product’s pharmacodynamics and
pharmacokinetics.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Nov 15
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.